Justin Dexter, MD
Ophthalmology · Oswego, NYNPI 1336309723
Payments from drug & device makers
Across 674 payments — averaging $297.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alcon Research LLC$140K
- Sight Sciences, Inc.$36K
- Alcon$16K
- Ocular Therapeutix, Inc.$1K
- Ivantis, Inc$1K
- AbbVie$893
- plus $5K from 27 others
What the payments were for
- Consulting fees$10,50017%
- Speaking & faculty fees$26,94745%
- Travel & lodging$4,8118%
- Food & beverage$17,94030%
- Education$1130%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alcon Research LLC | 45 | $140,275 |
| Sight Sciences, Inc. | 97 | $36,037 |
| Alcon | 230 | $16,114 |
| Ocular Therapeutix, Inc. | 48 | $1,280 |
| Ivantis, Inc | 18 | $1,031 |
| AbbVie(2 entities) | 47 | $893 |
| Glaukos Corporation | 16 | $617 |
| Amgen(2 entities) | 13 | $514 |
| Oyster Point Pharma, Inc. | 23 | $459 |
| Harrow Eye, LLC | 18 | $445 |
| Biotissue Holdings Inc. | 11 | $433 |
| Johnson & Johnson Surgical Vision, Inc. | 20 | $407 |
| Novartis | 20 | $302 |
| Sun Pharmaceutical Industries Inc. | 11 | $259 |
| Tarsus Pharmaceuticals, Inc. | 8 | $179 |
| Bausch & Lomb Americas Inc. | 9 | $173 |
| Kala Pharmaceuticals, Inc. | 7 | $144 |
| Aerie Pharmaceuticals, Inc. | 8 | $134 |
| Mallinckrodt Enterprises LLC | 1 | $121 |
| Thea Pharma Inc. | 5 | $118 |
| LKC Technologies, Inc. | 1 | $111 |
| Spark Therapeutics, Inc. | 1 | $106 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 3 | $81 |
| Carl Zeiss Meditec USA, Inc. | 1 | $67 |
| NEW World Medical,inc. | 3 | $60 |
| Beaver-visitec International, Inc. | 2 | $39 |
| Mallinckrodt Hospital Products Inc. | 1 | $37 |
| Rxsight Inc | 2 | $35 |
| Apellis Pharmaceuticals, Inc. | 1 | $23 |
| Rayner Intraocular Lenses Limited | 1 | $21 |
| Dompe US, Inc. | 1 | $17 |
| Omeros Corporation | 1 | $14 |
| Eyevance Pharmaceuticals LLC | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- OMNI$19,145
- OMNI(R) SURGICAL SYSTEM (US)$15,174
- Hydrus Microstent$9,810
- SION SURGICAL INSTRUMENT$2,783
- Clareon$664
- DEXTENZA$607
- ORA$270
- AcrySof IQ VIVITY IOL$266
- AcrySof IQ PanOptix$241
- Prokera$241
- ARGOS$150
- ILUX$141
- Unity$133
- PanOptix$129
- AmnioGraft$129
- TEPEZZA$125
- AcrySof IQ PanOptix UV IOL$122
- Clareon PanOptix Pro$122
- ACTHAR$121
- Luxor$116
How this compares
$200,559 in reported general payments places this provider in the 95th percentile of 1,587 ophthalmology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XdemvyLotilaner | 36 | $65,623 |
| RestasisCyclosporine | 25 | $46,046 |
| TyrvayaVarenicline Tartrate | 22 | $18,631 |
| Ketorolac Tromethamine | 362 | $18,054 |
| RocklatanNetarsudil Mesylat/Latanoprost | 14 | $15,389 |
| RhopressaNetarsudil Mesylate | 23 | $13,391 |
| Prednisolone Acetate | 261 | $13,005 |
| LumiganBimatoprost | 16 | $8,741 |
| Cyclosporine | 11 | $8,329 |
| Latanoprost | 400 | $5,022 |
| Timolol Maleate | 54 | $3,932 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 17 | $3,847 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 157 | $2,700 |
| Ofloxacin | 231 | $2,417 |
| Brimonidine Tartrate | 96 | $1,798 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Tarsus Pharmaceuticals, Inc.Xdemvy | $179 | $65,62336 claims |
| AbbVieRestasis, Lumigan | $893 | $54,78741 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa | $134 | $28,78037 claims |
| Oyster Point Pharma, Inc.Tyrvaya | $459 | $18,63122 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,587 ophthalmology providers in New York.
Other ophthalmology in Oswego
- Douglas JabsNew York$24.3M
- David RubaltelliBrooklyn$8.9M
- Philip FerroneGreat Neck$5.8M
- Eric DonnenfeldGarden City$2.6M
- Nathan RadcliffeNew York$2.4M
- Glenn StollerRockville Centre$2.1M
- Richard SpaideNew York$1.7M
- Paul HartmanRochester$1.6M
- Jason SlakterNew York$1.2M
- David ChuNew York$1.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.